Opportunities and Challenges of AAV Gene Therapy, GentleGen: Full-chain technical support for AAV drug development!

Release time:2026-06-26

Adeno-Associated Virus (AAV) vectors have become the dominant platform in the gene therapy field. To date, eight AAV gene therapy drugs have been approved worldwide, covering multiple serious genetic diseases such as spinal muscular atrophy, hemophilia B, and Duchenne muscular dystrophy. The successful launch of these drugs marks a milestone leap in AAV gene therapy from the laboratory to clinical applications.

640 (12)

However, the clinical translation of AAV gene therapy still faces multiple challenges. Discrepancies between preclinical model predictions and clinical outcomes, immunogenicity risks, liver toxicity issues, and bottlenecks in large-scale production all restrict further development in this field.

640 (1)

Against this backdrop, building a comprehensive AAV vector development and quality analysis system has become key to successfully launching gene therapy drugs.

Core technical challenges in AAV carrier development

Carrier capacity limit:AAV packaging capacity is only about 4.7 kb, which cannot accommodate most full-length genes. New technologies (such as AAVLINK) achieve over 11 kb of gene delivery through splitting and recombination, breaking through capacity bottlenecks.

640 (13)

Immunogenicity issues: 30-50% of the population has pre-stored neutralizing antibodies; high doses of AAV can cause adverse reactions such as hepatotoxicity and thrombocytopenia. Optimizing vector sequences and reducing CpG content can lower immunogenicity.

640 (2)

Targeting and safety: AAV tends to accumulate in the liver during systemic administration. Coating modifications (such as AAV9-G266A) can reduce liver distribution while maintaining target tissue transduction, thereby improving safety.

GentleGen: Full-chain technical support for AAV drug development

NGSafety® platform: empowering AAV drug quality analysis

During the development of AAV drugs, quality control and safety evaluation run throughout the entire process from R&D to production. GentleGen's NGSafety® technology platform, including a series of solutions such as AAV-NGSafety®, meets regulatory regulatory requirements for gene therapy drug quality through strict quality control systems, precise sample preparation processes, and professional bioinformatics analysis capabilities.

The platform has successfully assisted multiple clients' R&D pipelines in completing China-US IND filings, covering the following key quality attribute analyses of AAV carriers:

Vector genome integrity analysis: High-throughput sequencing is used to assess the integrity of the AAV vector genome, ITR structural integrity, and potential replication AAV contamination;

Integration site analysis: Detecting the integration tendency of AAV vectors in the host genome and assessing the risk of insertion mutations;

Impurity analysis: identification of residual host proteins, nucleases, empty capsids, and other process-related impurities;

Replicable AAV detection: Quantitatively analyzes replicable AAV contamination levels to ensure product safety

One-stop gene services: full-chain support from synthesis to analysis

GentleGen has built a one-stop gene service platform covering gene synthesis, oligonucleotide synthesis, Sanger sequencing, high-throughput sequencing, gene editing, and protein expression.

For AAV gene therapy development, this platform provides the following key support:

Vector Design and Construction: Provides services such as gene synthesis of AAV vector plasmids, ITR sequence validation, and capsid mutant construction, supporting the development and optimization of novel AAV serotypes.

Production cell line analysis: Using NGS technology to analyze the genetic stability of production cell lines, ensuring consistency and reliability during AAV production.

Process Development Support: By combining high-throughput sequencing and automation technologies, we accelerate the development and optimization of AAV production processes, addressing the challenges of large-scale production of high-titer AAV.

GentleGen provides regulatory compliance with professional solutions for AAV gene therapy drug development and quality control through the NGSafetty® platform and one-stop gene services. Throughout this process, a comprehensive quality analysis and safety evaluation system will continue to safeguard the safety and efficacy of gene therapy drugs. For more details about related services, you can send an email to marketing@gentlegen.com.

Contact Sales

Contact Sales Assistant

Contact PM